Hypertension: management perspectives

被引:5
作者
Borghi, Claudio [1 ,2 ]
Cicero, Arrigo F. G. [1 ,2 ]
机构
[1] S Orsola Malpighi Univ Hosp, Internal Med Aging & Kidney Dis Dept, I-40138 Bologna, Italy
[2] Univ Bologna, Internal Med Aging & Kidney Dis Dept, Bologna, Italy
关键词
blood pressure; diagnosis; hypertension; management; perspectives; therapeutics; TREATMENT-RESISTANT HYPERTENSION; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; ARTERIAL STIFFNESS; PRIMARY PREVENTION; MORTALITY; GUIDELINES; RECEPTOR; EVENTS; TRENDS;
D O I
10.1517/14656566.2012.708733
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: The increasing worldwide prevalence of hypertension and the related increase in cost due to diagnosis, management and negative outcomes forces public health institutions and clinical researchers to find new strategies to improve blood pressure (BP) control. So what are the possible future perspectives for high BP management? Areas covered: Three main points are briefly discussed in this article: individualized therapy, the known genetic contribution to hypertension development and control, and the improvement of disease management, including perspectives on new antihypertensive drug development. Expert opinion: It is likely that the integration of the best available current knowledge with recent diagnostic and therapeutic achievements for the management of hypertension prevention and treatment will lead to the early detection of at-risk conditions, early diagnosis, and individualized and efficacious treatment. The most promising antihypertensive drugs currently in development are innovative renin-angiotensin-aldosterone system modulators. Further drugs have potentially interesting mechanisms of action, but renalase analogs are in the very early phases of development, and available endothelin antagonists have a poor safety profile.
引用
收藏
页码:1999 / 2003
页数:5
相关论文
共 39 条
[1]   DASH lowers blood pressure in obese hypertensives beyond potassium, magnesium and fibre [J].
Al-Solaiman, Y. ;
Jesri, A. ;
Mountford, W. K. ;
Lackland, D. T. ;
Zhao, Y. ;
Egan, B. M. .
JOURNAL OF HUMAN HYPERTENSION, 2010, 24 (04) :237-246
[2]   Stereochemical Requirements for the Mineralocorticoid Receptor Antagonist Activity of Dihydropyridines [J].
Arhancet, Graciela B. ;
Woodard, Scott S. ;
Dietz, Jessica D. ;
Garland, Danny J. ;
Wagner, Grace M. ;
Iyanar, Kaliappan ;
Collins, Joe T. ;
Blinn, James R. ;
Numann, Randal E. ;
Hu, Xiao ;
Huang, Horng-Chih .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (10) :4300-4304
[3]   Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study [J].
Banegas, Jose R. ;
Lopez-Garcia, Esther ;
Dallongeville, Jean ;
Guallar, Eliseo ;
Halcox, Julian P. ;
Borghi, Claudio ;
Masso-Gonzalez, Elvira L. ;
Jimenez, Francisco J. ;
Perk, Joep ;
Gabriel Steg, Philippe ;
De Backer, Guy ;
Rodriguez-Artalejo, Fernando .
EUROPEAN HEART JOURNAL, 2011, 32 (17) :2143-2152
[4]   Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study [J].
Borghi, C ;
Dormi, A ;
Veronesi, M ;
Sangiorgi, Z ;
Gaddi, A .
AMERICAN HEART JOURNAL, 2004, 148 (02) :285-292
[5]  
Borghi C, 2010, CARDIOL CLIN PRACT, V2, P109
[6]   Pharmacogenetics of Antihypertensive Response [J].
Campbell, Catherine Y. ;
Blumenthal, Roger S. .
HYPERTENSION, 2012, 59 (06) :1094-1096
[7]  
Campbell DJ, 2012, CURR PHARM DESIGN, V18, P1005
[8]   Relationship between blood pressure, cholesterolemia and serum apolipoprotein B in a large population sample: the Brisighella Heart Study [J].
Cicero, Arrigo F. G. ;
D'Addato, Sergio ;
Veronesi, Maddalena ;
Rosticci, Martina ;
Santi, Francesca ;
Dormi, Ada ;
Borghi, Claudio .
JOURNAL OF HYPERTENSION, 2012, 30 (03) :492-496
[9]  
Cohen Jerome D, 2009, Manag Care, V18, P51
[10]   Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials [J].
Dickinson, HO ;
Mason, JM ;
Nicolson, DJ ;
Campbell, F ;
Beyer, FR ;
Cook, JV ;
Williams, B ;
Ford, GA .
JOURNAL OF HYPERTENSION, 2006, 24 (02) :215-233